Introduction: People with Parkinson's disease (PD) may have difficulty maintaining good oral hygiene due to their motor impairments. This generally leads to a higher prevalence of oral infections, including periodontal disease. To date, no study has addressed this issue in a French population. Objective: The aim of the study, part of the PARKIDENT clinical trial, was to assess the periodontal health of people with PD and to evaluate changes in their periodontal parameters 6 months after receiving hygiene advice. Methods: Data were collected from 40 participants at both baseline and 6-month follow-up. These data included demographic information and an assessment of the participants' PD stage. Oral health assessments included oral hygiene and periodontal status. Microbiological samples were also collected and the data collected during the two visits were compared. Results: Forty people with PD participated in the study. An improvement in oral hygiene habits and a reduction in the plaque index were observed at follow-up. The frequency of patients with significant periodontal pockets (> 6mm) was also reduced (from 20% to 3%). The improvement in these periodontal parameters was associated with a reduction in bacterial load, particularly for Treponema denticola (p=0.003). Conclusion: The study suggests that hygiene advice can improve periodontal health in patients with PD, potentially preventing tooth loss and improving their quality of life. Clinical Significance: This study, the first in France on the periodontal health of people with PD, suggests that dental visits and hygiene advice can improve their oral health.

The authors have declared no competing interest.

NCT03827551

This work was supported by France Parkinson.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The research protocol was reviewed and approved by a French regional ethics committee, the Comite de Protection des Personnes (CPP) Sud-Est III, approval number: Eudract 2018-A02773-52.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors